Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Breakthrough Cancer Pain According to European Guidelines

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients of any ethnic origin of ≥ 18 years.~* Patients diagnosed with locally advanced or recurrent metastatic cancer (histologic or cytologic diagnosis), with BTcP, as assessed by the Investigator.~* Opioid-tolerant patients receiving doses of oral morphine equivalent daily doses (OMEDD) of at least 60 mg.~* Drugs for BTcP treatment, if any, must be used according to the relevant SmPC.~* Eastern Cooperative Oncology Group (ECOG) performance status with a score of 0, or 1, or 2.~* Patients with life expectancy \> 3 months.~* Patients legally capable of giving their consent to participate in the study and available to sign and date the written informed consent.~Exclusion Criteria:~* Patients with previous or current history of a clinically significant neurological/psychiatric disorder and/or any substance abuse or dependence that, according to the Investigator's judgement, can impair the study end-points/results.~* Patients who have been taking antidepressants and/or drugs acting on pain and who take them on a regular basis during the observation period, can be enrolled.~* Any medical condition or situation complicating the collection of study data, as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GROUP A: Patients adherent to BTcP European Guidelines (Type: None): None
- GROUP B: Patients non Adherent to BTcP European Guidelines (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).